As of 2026-04-21, the EV/EBITDA ratio of Pulmonx Corp (LUNG) is -0.54. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LUNG's latest enterprise value is 27.32 mil USD. LUNG's TTM EBITDA according to its financial statements is -50.62 mil USD. Dividing these 2 quantities gives us the above LUNG EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.8x - 13.7x | 11.8x |
| Forward P/E multiples | 10.3x - 11.2x | 10.8x |
| Fair Price | (11.57) - (12.65) | (12.71) |
| Upside | -914.8% - -990.7% | -995.0% |
| Date | EV/EBITDA |
| 2026-04-21 | -0.56 |
| 2026-04-20 | -0.54 |
| 2026-04-17 | -0.58 |
| 2026-04-16 | -0.57 |
| 2026-04-15 | -0.61 |
| 2026-04-14 | -0.54 |
| 2026-04-13 | -0.56 |
| 2026-04-10 | -0.50 |
| 2026-04-09 | -0.49 |
| 2026-04-08 | -0.43 |
| 2026-04-07 | -0.42 |
| 2026-04-06 | -0.49 |
| 2026-04-02 | -0.46 |
| 2026-04-01 | -0.42 |
| 2026-03-31 | -0.43 |
| 2026-03-30 | -0.34 |
| 2026-03-27 | -0.33 |
| 2026-03-26 | -0.39 |
| 2026-03-25 | -0.44 |
| 2026-03-24 | -0.45 |
| 2026-03-23 | -0.51 |
| 2026-03-20 | -0.49 |
| 2026-03-19 | -0.51 |
| 2026-03-18 | -0.59 |
| 2026-03-17 | -0.71 |
| 2026-03-16 | -0.70 |
| 2026-03-13 | -0.76 |
| 2026-03-12 | -0.84 |
| 2026-03-11 | -0.85 |
| 2026-03-10 | -0.84 |
| 2026-03-09 | -0.87 |
| 2026-03-06 | -1.04 |
| 2026-03-05 | -0.70 |
| 2026-03-04 | -0.56 |
| 2026-03-03 | -0.63 |
| 2026-03-02 | -0.63 |
| 2026-02-27 | -0.67 |
| 2026-02-26 | -0.72 |
| 2026-02-25 | -0.72 |
| 2026-02-24 | -0.61 |
| 2026-02-23 | -0.59 |
| 2026-02-20 | -0.61 |
| 2026-02-19 | -0.54 |
| 2026-02-18 | -0.54 |
| 2026-02-17 | -0.60 |
| 2026-02-13 | -0.58 |
| 2026-02-12 | -0.54 |
| 2026-02-11 | -0.56 |
| 2026-02-10 | -0.56 |
| 2026-02-09 | -0.64 |